ArticleTurkish journal of medical sciences2025
The effects of liraglutide on expressions of insulin secretion and beta cell survive associated GPCR genes in pancreatic beta cells.
Article in Turkish journal of medical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Gpr75 Deletion in Adipocytes Protects From Diet-Induced Obesity: Changes in Glucose Homeostasis and Inflammatory Responses.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/aim: Liraglutide as a long-acting glucagon-like peptide drug has anti-hyperglycemic and antiobesity effects. G protein-coupled receptors (GPCRs) are well-known drug target molecules that conduct critical signaling pathways related with diseases. Research has confirmed the role of many GPCRs genes in the regulation of pancreatic beta cell functions and insulin secretion. Liraglutide dependent expressional changes in GPCR genes may let us determine new drug targets. Materials and methods: Therefore, we investigated the changes in expression of GPR75, GPR56, GLP1R, M3R, and CB1R genes, which are the GPCR family members, in response to liraglutide treatment in the NIT-1 mouse pancreatic beta cells in this study. Changes at the mRNA levels of these GPCR genes were determined by a qPCR and the ddCT method, and using a control gene and untreated control groups. Results: We found statistically significant increases at the mRNA levels of GPR75, GPR56, M3R, and CB1R genes with 10nM of liraglutide at min 60, while there was no time and dose-dependent change in all of the genes investigated. We detected that the GLP1R gene expressions were stable amongst different time points and doses of liraglutide, except for a statistically significant decrease in the GLP1R gene expression in response to 1000nM of liraglutide treatment compared to 10nM and 100nM concentrations. Conclusion: Our results indicate that in vitro liraglutide administration in pancreatic beta cells appears to increase the expressions of GPR75, GPR56, M3R and CB1R genes which have already been related to insulin secretion and beta cell survive. Liraglutide may exert this effect through the GLP1R or other cellular pathways undescribed yet. Combined usage of liraglutide and the specific ligands of GPR75, GPR56, M3R, and CB1R may provide a better response in terms of insulin secretion and beta cell survival, making them good targets for antidiabetic and antiobesity therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.